Since the end of May 2019, around 40% of patients with HR+/HER2- breast cancer can count on a new drug developed by Novartis and approved by the FDA. This new development is another important step into the field of precision medicine. Piqray® is indeed specific to HR+/HER2- breast cancer with PIK3CA mutations.
Therefore, the use of reliable genetic diagnostic tests to assess the presence and characteristics of a mutation on this gene is essential in the therapeutic decision making process.
With a very active research in this field, more and more precision medicine treatments will appear in the upcoming years and the need for highly precise and reliable genetic diagnostic companion tests will increase drastically.
More on Novartis website: www.novartis.com
